Use of prothrombin complex concentrate in warfarin anticoagulation reversal in the emergency department: a quality improvement study of administration delays
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1472-6963
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Use of prothrombin complex concentrate in warfarin anticoagulation reversal in the emergency department: a quality improvement study of administration delays ; volume:15 ; number:1 ; day:15 ; month:3 ; year:2015 ; pages:1-10 ; date:12.2015
BMC health services research ; 15, Heft 1 (15.3.2015), 1-10, 12.2015
- Creator
-
Bordeleau, Simon
- Contributor
-
Poitras, Julien
Marceau, Danièle
Breton, Carolle
Beaupré, Pierre
Archambault, Patrick M.
SpringerLink (Online service)
- DOI
-
10.1186/s12913-015-0775-6
- URN
-
urn:nbn:de:1111-2016110519914
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bordeleau, Simon
- Poitras, Julien
- Marceau, Danièle
- Breton, Carolle
- Beaupré, Pierre
- Archambault, Patrick M.
- SpringerLink (Online service)
Other Objects (12)
The effects between andexanet alpha and four-factor prothrombin complex concentrate on DOACs anticoagulation reversal
Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal
Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy
3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors
Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis
Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
Preparation of a Nonthrombogenic Prothrombin Complex Concentrate
The effects between andexanet alpha and four-factor prothrombin complex concentrate on DOACs anticoagulation reversal
Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal
Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy
3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors
Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis
Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
Preparation of a Nonthrombogenic Prothrombin Complex Concentrate
The effects between andexanet alpha and four-factor prothrombin complex concentrate on DOACs anticoagulation reversal
Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal
Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy
3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors
Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis
Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation